Literature DB >> 22567177

(68)Ga-Labeling of RGD peptides and biodistribution.

Elisabeth Blom, Irina Velikyan, Sergio Estrada, Håkan Hall, Taj Muhammad, Chenmin Ding, Manoj Nair, Bengt Långström.   

Abstract

Several peptides comprising Arg-Gly-Asp (RGD) domain and macrocyclic chelator were labeled with (68)Ga for the imaging of angiogenesis. The analogues varied in peptide constitution, linker and chelator type. The labeling efficiency did not vary with the peptide constitution and linker type, but depended on the chelator type. Four of the compounds containing 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) chelator were labeled at 90 ± 5°C using conventional or microwave heating reaching 90% of (68)Ga incorporation after 5 and 2 min respectively, when the concentration of the precursor was 2.5 μM. The compound having 2,2',2''-(1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA) as the chelator could be labeled at room temperature within 5 min using 2.5 μM peptide precursor. Two of the compounds contained a poly (ethylene glycol) (PEG) linker to the chelator. The biodistribution of the analogues was studied in male rats.

Entities:  

Keywords:  68Ga; RGD; biodistribution

Year:  2012        PMID: 22567177      PMCID: PMC3342714     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  20 in total

1.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.

Authors:  Raymond M Schiffelers; Gerben A Koning; Timo L M ten Hagen; Marcel H A M Fens; Astrid J Schraa; Adriënne P C A Janssen; Robbert J Kok; Grietje Molema; Gert Storm
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

2.  NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging.

Authors:  Bård Indrevoll; Grete Mørk Kindberg; Magne Solbakken; Emma Bjurgert; John Henrik Johansen; Hege Karlsen; Marivi Mendizabal; Alan Cuthbertson
Journal:  Bioorg Med Chem Lett       Date:  2006-09-26       Impact factor: 2.823

3.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.

Authors:  Marcel L Janssen; Wim J Oyen; Ingrid Dijkgraaf; Leon F Massuger; Cathelijne Frielink; D Scott Edwards; Milind Rajopadhye; Henk Boonstra; Frans H Corstens; Otto C Boerman
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

Review 4.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

5.  Liposomes modified with cyclic RGD peptide for tumor targeting.

Authors:  Praveen K Dubey; Vivek Mishra; Sanyog Jain; Sunil Mahor; S P Vyas
Journal:  J Drug Target       Date:  2004-06       Impact factor: 5.121

6.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.

Authors:  Xiaoyuan Chen; Shuang Liu; Yingping Hou; Michel Tohme; Ryan Park; James R Bading; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2004 Sep-Oct       Impact factor: 3.488

7.  (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.

Authors:  Zi-Bo Li; Kai Chen; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-19       Impact factor: 9.236

8.  68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression.

Authors:  Clemens Decristoforo; Ignacio Hernandez Gonzalez; Janette Carlsen; Marco Rupprich; Marc Huisman; Irene Virgolini; Hans-Jürgen Wester; Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-28       Impact factor: 9.236

Review 9.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  9 in total

1.  (68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes.

Authors:  Renata Madru; Thuy A Tran; Johan Axelsson; Christian Ingvar; Adnan Bibic; Freddy Ståhlberg; Linda Knutsson; Sven-Erik Strand
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

2.  68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull.

Authors:  Akintunde Orunmuyi; Moshe Modiselle; Thabo Lengana; Thomas Ebenhan; Mariza Vorster; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-02-12

3.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

4.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

5.  In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging probe.

Authors:  Jun Zhou; Guiyang Hao; Hong Weng; Yi-Ting Tsai; David W Baker; Xiankai Sun; Liping Tang
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

6.  In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.

Authors:  Felix Fuge; Dennis Doleschel; Anne Rix; Felix Gremse; Axel Wessner; Oliver Winz; Felix Mottaghy; Wiltrud Lederle; Fabian Kiessling
Journal:  Eur Radiol       Date:  2014-09-09       Impact factor: 5.315

Review 7.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

8.  In vivo pharmacological activity and biodistribution of S-nitrosophytochelatins after intravenous and intranasal administration in mice.

Authors:  Lamia Heikal; Anna Starr; Gary P Martin; Manasi Nandi; Lea Ann Dailey
Journal:  Nitric Oxide       Date:  2016-06-24       Impact factor: 4.427

9.  Comparative Evaluation of Radiochemical and Biological Properties of 131I- and [99mTc]Tc(CO)3-Labeled RGD Analogues Planned to Interact with the αvβ3 Integrin Expressed in Glioblastoma.

Authors:  Danielle V Sobral; Leonardo L Fuscaldi; Ana Claudia R Durante; Fernanda F Mendonça; Larissa R de Oliveira; Ana Cláudia C Miranda; Jorge Mejia; Wagner R Montor; Marycel F de Barboza; Luciana Malavolta
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.